A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Cavosonstat Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT04600778 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

OTHER: placebo
DRUG: Cavosonstat 5 mg
DRUG: Cavosonstat 10 mg
DRUG: Cavosonstat 25 mg

Sponsor

GSNOR Therapeutics, Inc.